e-therapeutics has become the latest UK biotech to say it plans to delist from the Alternative Investment Market (AIM) in another blow to the reputation of the London Stock Exchange’s junior market.
According to chief executive Ali Mortazavi, the proposal – which will be put to shareholders at a meeting on 29th April – had been more than a year in the making and came after a disappointing capital raise drive that e-therapeutics took on the road in February and March of this year.
